Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
about
Acute promyelocytic leukemia: where did we start, where are we now, and the futureATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Deregulated proliferation and differentiation in brain tumors.The role of retinoic acid receptors in the signal pathway of all-trans retinoic acid-induced differentiation in adriamycin-induced podocyte injury.Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-κB signaling.All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.Arsenic Primes Human Bone Marrow CD34+ Cells for Erythroid DifferentiationPML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia.The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulationComprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancersFucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.A Dialog on the First 20 Years of PML Research and the Next 20 Ahead.Retinoid receptor signaling and autophagy in acute promyelocytic leukemia.Retinoic acid as a therapeutic option in Alzheimer's disease: a focus on cholinergic restoration.LRRC25 plays a key role in all-trans retinoic acid-induced granulocytic differentiation as a novel potential leukocyte differentiation antigen.PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response.Long-term outcome of 31 cases of refractory acute promyelocytic leukemia treated with compound realgar natural indigo tablets administered alternately with chemotherapy.Eya2, a Target Activated by Plzf, Is Critical for PLZF-RARA-Induced Leukemogenesis.PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells.Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis.Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16 E6/E7 for further therapeutic directions in renal cell carcinoma.The complex relationship of Tribbles pseudokinase 1, PML/RARA and C/EBPα in leukemia: two possible couples but not a trio.Blood's 70th anniversary: arsenic--from poison pill to magic bullet.Non-classical Transcriptional Activity of Retinoic Acid.Circular RNAs: Biogenesis, Function, and a Role as Possible Cancer Biomarkers.Non-coding RNA networks in cancer.FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase.Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cellsArsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells
P2860
Q26830385-5ABF4110-A9D4-4907-9D18-D6AE54103797Q34046794-C371BCC5-0465-4A4F-BA61-16D40F61CE49Q34859989-3D98729D-18B8-4265-84F6-3353FCA5F6D4Q35171746-9944DE6C-DA8A-425E-A712-1FDE459047EBQ35491865-92EB32EA-C1AF-44AA-887C-151CD48A7FB9Q35654471-3FE428A1-ACA0-46E9-BA4E-28FCA0C2D110Q35779741-4AD4B5F2-2174-469C-AF57-5A83FA7A6D75Q36191698-A97782C3-E436-4610-BB6A-33F62ACE7925Q36303245-9147004A-B6F3-4AA6-ABE3-81A2C963A6D4Q36796264-D276A142-B87B-40E5-AA5A-A3A9C6C4E46EQ36941941-19B9A023-E297-4841-8C5F-9F79FC4B56F2Q37103762-E7ED3ACB-048F-4E66-9AD6-CC822F97FC97Q37150061-E7830D4C-ECBC-491C-B26F-21C060F680F2Q37278032-88FD4D43-FEA0-4365-A7DE-E92E2FE6F3EEQ37564637-D55D6224-1DDE-476D-9CAC-D07DB7F1B427Q37712353-D7BEDE60-8348-49C8-8E20-5C8257E4B320Q38191626-BF1F7F88-9AED-4AC4-B7C9-9684B0E866F2Q38201532-881871EE-9F20-4246-872D-7981ECC88147Q38356258-C1365B6E-6874-4CC5-98A4-DF9DECE2C763Q38768045-3EFCE4C2-0647-41B3-8F9D-AB1A4032FBD4Q38780205-D91786BF-B1D8-4441-A7E8-F89D84E01085Q38815484-1E762217-9A9C-4C6A-9757-6A32FC35B5EEQ38833595-D1ACAE51-BD34-4F30-B002-E1A4EA73422DQ38835020-95C9486A-7264-466F-9B33-C45202DDC00BQ38903506-7A84D45F-51F2-4812-8B74-FE0A67469506Q41433578-9F88C77D-D0B2-448B-ADF2-550855FE830BQ41637438-55FC67A0-D199-43D5-876E-9CE144BF0105Q42388549-EDBC0F35-70A3-4771-943B-E84BC091F59DQ42910730-E986C240-A1D3-49C8-A6A2-2D74A77F8E52Q48070294-767E997C-E381-488A-9410-6B16D7BBDD34Q48213837-6F329A4D-92B7-4C93-9368-74358EC89DFCQ49689803-EAB83BB3-6BF2-411D-8EB8-997F0E958105Q51236778-EEBD9887-20D9-4E47-B586-5BEF2489A00BQ55337080-83371F3A-9686-47C6-9A28-3210AD47273AQ58764406-109882C1-9945-40E5-9029-28851DC59744Q58793896-C07882B1-6632-446A-9EA3-4BBBF5AD8F50
P2860
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synergy against PML-RARa: targ ...... acute promyelocytic leukemia.
@en
Synergy against PML-RARa: targ ...... acute promyelocytic leukemia.
@nl
type
label
Synergy against PML-RARa: targ ...... acute promyelocytic leukemia.
@en
Synergy against PML-RARa: targ ...... acute promyelocytic leukemia.
@nl
prefLabel
Synergy against PML-RARa: targ ...... acute promyelocytic leukemia.
@en
Synergy against PML-RARa: targ ...... acute promyelocytic leukemia.
@nl
P2860
P921
P356
P1476
Synergy against PML-RARa: targ ...... n acute promyelocytic leukemia
@en
P2093
Guilherme Augusto Dos Santos
P2860
P304
P356
10.1084/JEM.20131121
P407
P577
2013-12-01T00:00:00Z